Item 7.01. Regulation FD Disclosure.
As previously reported, on August 17, 2020, Brickell Biotech, Inc. (the
"Company") received a notice from the Listing Qualifications Department of the
Nasdaq Stock Market ("Nasdaq") indicating that the Company was not in compliance
with the $1.00 per share minimum closing bid price requirement for continued
listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2)
(the "Rule").
On January 21, 2021, the Company received a letter from Nasdaq notifying the
Company that it had regained compliance with the Rule as a result of the closing
bid price of the Company's common stock being at $1.00 per share or greater for
the 11 consecutive business days from January 5, 2021 through January 20, 2021.
Accordingly, the Company has regained compliance with the Rule and Nasdaq
considers the matter closed.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses